23 related articles for article (PubMed ID: 26796064)
1. Dimeric 3,5-Bis(benzylidene)-4-piperidones: Tumor-Selective Cytotoxicity and Structure-Activity Relationships.
Das S; Roayapalley PK; Sakagami H; Umemura N; Gorecki DKJ; Hossain M; Kawase M; Das U; Dimmock JR
Medicines (Basel); 2024 Jan; 11(1):. PubMed ID: 38248717
[No Abstract] [Full Text] [Related]
2. Synthesis and lateral root-inducing activity of novel N-substituted-2-piperidones with a 1,4-benzodioxan ring.
Tsukada H; Yamada N; Taniguchi E; Kuwano E
Biosci Biotechnol Biochem; 2000 Oct; 64(10):2229-31. PubMed ID: 11129601
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis and Tumour-Selective Toxicity of Novel 1-[3-{3,5-Bis(benzylidene)-4-oxo-1-piperidino}-3-oxopropyl]-4-piperidone Oximes and Related Quaternary Ammonium Salts.
Roayapalley PK; Dimmock JR; Contreras L; Balderrama KS; Aguilera RJ; Sakagami H; Amano S; Sharma RK; Das U
Molecules; 2021 Nov; 26(23):. PubMed ID: 34885719
[TBL] [Abstract][Full Text] [Related]
4. 1-[4-(2-Aminoethoxy)phenylcarbonyl]-3,5-bis-(benzylidene)-4-oxopiperidines: a novel series of highly potent revertants of P-glycoprotein associated multidrug resistance.
Das U; Molnár J; Baráth Z; Bata Z; Dimmock JR
Bioorg Med Chem Lett; 2008 Jun; 18(12):3484-7. PubMed ID: 18513966
[TBL] [Abstract][Full Text] [Related]
5. Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones.
Hossain M; Das U; Umemura N; Sakagami H; Balzarini J; De Clercq E; Kawase M; Dimmock JR
Bioorg Med Chem; 2016 May; 24(10):2206-14. PubMed ID: 27073056
[TBL] [Abstract][Full Text] [Related]
6. 3,5-Bis(benzylidene)-4-oxo-1-phosphonopiperidines and related diethyl esters: Potent cytotoxins with multi-drug-resistance reverting properties.
Das S; Das U; Selvakumar P; Sharma RK; Balzarini J; De Clercq E; Molnár J; Serly J; Baráth Z; Schatte G; Bandy B; Gorecki DK; Dimmock JR
ChemMedChem; 2009 Nov; 4(11):1831-40. PubMed ID: 19802855
[TBL] [Abstract][Full Text] [Related]
7. Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
Das S; Das U; Sakagami H; Umemura N; Iwamoto S; Matsuta T; Kawase M; Molnár J; Serly J; Gorecki DK; Dimmock JR
Eur J Med Chem; 2012 May; 51():193-9. PubMed ID: 22409967
[TBL] [Abstract][Full Text] [Related]
8. CoMFA and CoMSIA studies on 1,3-bis(benzylidene)-3,4-dihydro-1H-naphthalen-2-one, 2,6-bis(benzylidene)cyclohexanone, and 3,5-bis(benzylidene)-4-piperidone series of cytotoxic compounds.
Patel MR; Dimmock JR; Talele TT
J Chem Inf Model; 2007; 47(6):2110-23. PubMed ID: 17944456
[TBL] [Abstract][Full Text] [Related]
9. 1-[3-(2-Hydroxyethylsulfanyl)propanoyl]-3,5-bis(benzylidene)-4-piperidones: A novel cluster of P-glycoprotein dependent multidrug resistance modulators.
Das U; Pati HN; Baráth Z; Csonka Á; Molnár J; Dimmock JR
Bioorg Med Chem Lett; 2016 Feb; 26(4):1319-21. PubMed ID: 26796064
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Investigation of 1-[4-(2-Aminoethoxy)Phenylcarbonyl]- 3,5-Bis-(Benzylidene)-4-Piperidones as Candidate Antineoplastic Agents: Our Last 15 Years Study.
Hossain M; Enci CE; Dimmock JR; Das U
Curr Med Chem; 2021; 28(13):2453-2464. PubMed ID: 32744955
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance.
Boumendjel A; Di Pietro A; Dumontet C; Barron D
Med Res Rev; 2002 Sep; 22(5):512-29. PubMed ID: 12210557
[TBL] [Abstract][Full Text] [Related]
12. [Antineoplastons--structure, chemical properties and mechanism of activity].
Kochman A; Bronowicz A
Postepy Hig Med Dosw; 1992; 46(6):659-68. PubMed ID: 1308583
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
